home

Cydan Development Announces Formation of Imara Inc. with $31M Series A Funding to Develop Therapeutic for Sickle Cell Disease

EVENTSbusinesswire2016-04-15 09:39 Read   63

Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improves the lives of people living with rare genetic diseases, today announced the launch of Imara, Inc. This is the second orphan drug company launched by Cydan since 2015. Imara will develop IMR-687, a disease-modifying therapeutic selected specifically for the treatment of sickle cell disease and other hemoglobinopathies. IMR-687 was discovered by H. Lundbeck A/S.

Contract Research Organization Participation in Clinical Trial Design Projected to Increase 206 Percent by 2020, According to Cutting Edge Information

EVENTSmarketwired2016-04-15 09:28 Read   96

Pharmaceutical and medical device teams plan to increasingly involve contract research organizations (CROs) in their clinical trial planning processes.

Redx Pharma Plc set for new HQ at Alderley Park

EVENTSredxpharma2016-04-15 09:21 Read   89

Redx Pharma Plc is to establish new headquarters at Alderley Park, Cheshire, creating a 74,000 sq. ft. state-of-the-art drug development facility that brings together its three subsidiary businesses onto one site.

Forbion to step up CNS investment activity after closing €183M fund

EVENTSfiercebiotech2016-04-15 09:10 Read   56

Forbion Capital Partners is set to step up its investment in central nervous system (CNS) biotechs. The European VC shop is committing to the strategy after observing a shift in the economics of CNS drug development, which it thinks makes biotechs in the field a more attractive target for its newly-closed €183 million ($207 million) FCF III fund.

Oculus Innovative Sciences Receives European Approval to Market Sinudox™ Indicated for Use in Nasal Irrigation

EVENTSglobenewswire2016-04-14 15:35 Read   133

Oculus Innovative Sciences, Inc. today announced the issuance of a new CE Mark in Europe for Microcyn®-based Sinudox™ solution, a formulation intended for nasal irrigation including the moistening of cuts, abrasions and lacerations located in the nasal cavity.

Speaker relates what to expect as an expert witness

EVENTSHEALIO2016-04-14 14:19 Read   66

Anyone who engages in expert testimony must know what is meant by standard of care, according to Christie L. Morse, MD, the immediate past chair of the AAO Ethics Committee and executive vice president of AAPOS.

EnsoData Raises $550K to Develop Software That Analyzes Sleep Data

EVENTSxconomy2016-04-14 13:34 Read   49

At an event last August featuring pitches from startups, EnsoData co-founder Chris Fernandez told audience members that his company was hoping to raise $300,000 in a seed funding round.

Valeant CEO Pearson bows to Senate committee after public scolding

EVENTSfiercepharma2016-04-14 13:08 Read   54

Valeant Pharmaceuticals' ($VRX) public reprimand must have worked. After balking at the idea last week, CEO Michael Pearson agreed to give a deposition to the Senate Special Committee on Aging.

In Shkreli's wake, KaloBios vows fair pricing. Will others follow?

EVENTSfiercepharma2016-04-14 12:45 Read   46

KaloBios ($KBIO) pledged a fair pricing oath last week as part of its corporate brand-saving maneuver away from one-time CEO and industry bête noire Martin Shkreli.

Drug Pricing, Presidential Politics, and Three Biotechs with Promise PTIE, DRRX, ABEO, AST

EVENTSthelifesciencesreport2016-04-14 11:06 Read   63

While the vagaries of the 2016 political season create uncertainty in the biotech and pharmaceutical sectors, companies are moving ahead with innovative cell therapies, gene therapies and new, safer ways to deliver addictive drugs, and investors find themselves in a position to play the development ideas with varying degrees of risk.

Medivation Said to Have Rebuffed Sanofi Takeover Approach

EVENTSbloomberg2016-04-14 10:14 Read   41

Medivation Inc. rebuffed a recent takeover approach from French drugmaker Sanofi, which is pursuing the U.S. company to expand its cancer treatment business, according to people familiar with the matter.

Kala Pharmaceuticals Announces Closing of $68 Million Series C Financing

EVENTSbusinesswire2016-04-14 09:56 Read   58

Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, announced that it has closed a highly oversubscribed $68 million Series C preferred stock financing, led by Longitude Capital.